GLS and cancer: Although small-molecule inhibitors that suppress glutamine transporters and glutaminase have exhibited synergistic effects with multiple anti-cancer agents in murine models [50–52], because of the intrinsic metabolic heterogeneity and flexibility within the TME, these efforts have met with limited success in the clinical setting [52–54].